Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event.

@article{Iskedjian2005EconomicEO,
  title={Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event.},
  author={Michael Iskedjian and John H. Walker and Trevor Gray and Colin Vicente and Thomas R Einarson and Adel Gehshan},
  journal={Multiple sclerosis},
  year={2005},
  volume={11 5},
  pages={542-51}
}
BACKGROUND Interferon beta-Ia (Avonex) 30 microg, intramuscular (i.m.), once weekly is efficacious in delaying clinically definite multiple sclerosis (CDMS) following a single demyelinating event (SDE). This study determined the cost effectiveness of Avonex compared to current treatment in delaying the onset of CDMS. METHODS A cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were performed from Ministry of Health (MoH) and societal perspectives. For CEA, the outcome of… CONTINUE READING